Related Experiment Video
Updated: Nov 6, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
[The utility of whole genome sequencing in rare disease diagnostics]
Maria Johansson Soller1, Ann Nordgren2, Hans Ehrencrona3
1docent, överläkare, Klinisk genetik, Karolinska universitetssjukhuset, Stockholm.
Abstract:
If a disease affects fewer than 1 in 2 000, the European Union defines it as a rare disease. Globally, about 300 million people live with a rare disease, and in Sweden about 400 000. There are approximately 7 000 different rare diseases. The clinical picture varies from a single symptom to complex patterns with multiple organs affected, often combined with cognitive and motor impairment. At least 72 % of all rare diseases are genetic and 70% have childhood onset. Many patients are undiagnosed and do not receive optimal treatment. Today, only 5% of rare diseases have an approved treatment option. With modern genetic high throughput techniques, many disease-causing mutations are identified, increasing the possibility of personalized treatment and prevention strategies, designed by the individual's genetic conditions, i.e. precision medicine.
Related Concept Videos
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Modern Molecular Taxonomy
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Genomics
Evolutionary Relationships through Genome Comparisons

